{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T23:50:56Z","timestamp":1778284256432,"version":"3.51.4"},"reference-count":16,"publisher":"Japanese Society of Internal Medicine","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,12,15]]},"DOI":"10.2169\/internalmedicine.3054-19","type":"journal-article","created":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T22:03:07Z","timestamp":1566338587000},"page":"3593-3596","source":"Crossref","is-referenced-by-count":2,"title":["Bacteriologically Determined &lt;i&gt;De Novo&lt;\/i&gt; Tuberculosis during Tumor Necrosis Factor-\u03b1 Inhibitor Therapy"],"prefix":"10.2169","volume":"58","author":[{"given":"Gen","family":"Takahashi","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Isesaki Municipal Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Isesaki Municipal Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Isesaki Municipal Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Ohsawa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Isesaki Municipal Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniaki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Isesaki Municipal Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Isesaki Municipal Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Hisada","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Gunma University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 1098-1104, 2001.","DOI":"10.1056\/NEJMoa011110"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Supply P, Allix C, Lesjean S, et al. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of <i>Mycobacterium tuberculosis<\/i>. J Clin Microbiol 244: 4498-4510, 2006.","DOI":"10.1128\/JCM.01392-06"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Singh J, Puri AS, Sachdeva S, Sakhuja P, Arivarasan K. Rectal tuberculosis after infliximab therapy despite negative screening for latent tuberculosis in a patient with ulcerative colitis. Intest Res 14: 183-186, 2016.","DOI":"10.5217\/ir.2016.14.2.183"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Debeuckelaere C, De Munter P, Van Bleyenbergh P, et al. Tuberculosis infection following anti-TNF therapy in inflammatory bowel disease, despite negative screening. J Crohns Colitis 8: 550-557, 2014.","DOI":"10.1016\/j.crohns.2013.11.008"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. O&apos;Dowd C, Kewin P, Morris J, Cotton M. Tuberculosis complicated by immune reconstitution inflammatory syndrome in a patient on anti-TNF\u03b1 therapy for Crohn&apos;s disease. BMJ Case Rep 2011: bcr0920103376, 2011.","DOI":"10.1136\/bcr.09.2010.3376"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Arend SM, Leyten EM, Franken WP, Huisman EM, van Dissel JT. A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis 45: 1470-1475, 2007.","DOI":"10.1086\/522993"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Iwamoto T, Grandjean L, Arikawa K, et al. Genetic diversity and transmission characteristics of beijing family strains of <i>mycobacterium tuberculosis<\/i> in Peru. PLoS One 7: e49651, 2012.","DOI":"10.1371\/journal.pone.0049651"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Borgdorff MW, van Soolingen D. The re-emergence of tuberculosis: what have we learnt from molecular epidemiology? Clin Microbiol Infect 19: 889-901, 2013.","DOI":"10.1111\/1469-0691.12253"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Byun JM, Lee CK, Rhee SY, et al. The risk of tuberculosis in Korean patients with inflammatory bowel disease receiving tumor necrosis factor-\u03b1 blockers. J Korean Med Sci 30: 173-179, 2015.","DOI":"10.3346\/jkms.2015.30.2.173"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Dhasmana D.J., Dheda K., Ravn P, et al. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy. Drugs 68: 191-208, 2008.","DOI":"10.2165\/00003495-200868020-00004"},{"key":"11","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1097\/QAD.0b013e32833dfc68","volume":"24","author":"G1 Meintjes","year":"2010","unstructured":"11. Meintjes G1, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 24: 2381-2390, 2010.","journal-title":"AIDS","ISSN":"https:\/\/id.crossref.org\/issn\/0269-9370","issn-type":"print"},{"key":"12","unstructured":"12. Tanaka T, Sekine A, Tsunoda Y, et al. Central nervous system manifestations of tuberculosis-associated immune reconstitution inflammatory syndrome during adalimumab therapy: a case report and review of the literature. Intern Med 54: 847-851, 2015."},{"key":"13","unstructured":"13. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64: 625-639, 2012."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ding T, Ledingham J, Luqmani R, et al. Standards, Audit and Guidelines Working Group of BSR Clinical Affairs Committee; BHPR. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) 49: 2217-2219, 2010.","DOI":"10.1093\/rheumatology\/keq249a"},{"key":"15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00002030-200401230-00015","volume":"18","author":"RS Wallis","year":"2004","unstructured":"15. Wallis RS, Kyambadde P, Johnson JL, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 18: 257-264, 2004.","journal-title":"AIDS","ISSN":"https:\/\/id.crossref.org\/issn\/0269-9370","issn-type":"print"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Matsumoto T, Tanaka T. Continuation of Anti-TNF-Therapy for rheumatoid arthritis in patients with active tuberculosis reactivated during anti-TNF Medication is more beneficial than its cessation. J Infect Dis Ther 3: 35-37, 2015.","DOI":"10.14205\/2310-9386.2015.03.01.6"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/24\/58_3054-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T23:51:30Z","timestamp":1664149890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/24\/58_3054-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,15]]},"references-count":16,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3054-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,15]]}}}